Jessica Carmen Joins RoslinCT as Chief Commercial Officer
RoslinCT is excited to share the news of Jessica Carmen, Ph.D., joining its esteemed leadership team as the new Chief Commercial Officer. With an impressive background spanning over two decades in business development and marketing within the cell and gene therapy sector, Dr. Carmen brings a wealth of expertise. Most recently, she held the position of Vice President of Business Development at Kincell Bio, where she significantly advanced their commercial endeavors.
Responsibilities and Impact
In her new role at RoslinCT, Dr. Carmen is set to spearhead the company’s commercial initiatives. She will oversee a diverse array of activities ranging from marketing RoslinCT's prolific technical capabilities to driving new business opportunities and nurturing essential customer relationships. Dr. Carmen will work in tandem with the integrated global leadership team, collaborating closely with operations in vital life sciences hubs.
Leadership Perspective
Geoffrey Hamilton-Fairley, Executive Chairman of RoslinCT, expressed enthusiasm about Dr. Carmen’s appointment. He emphasized, “We are thrilled to welcome Jessica to RoslinCT to attract more cell therapy developers to our sites. She brings an extensive network and a deep understanding of the manufacturing process for cell-based medicines.” This sentiment highlights the significant role Dr. Carmen is poised to play in strengthening the connections within the industry.
Dr. Carmen's Vision
Dr. Carmen herself shared her excitement about joining RoslinCT, noting, “I look forward to driving the long-term growth of this company for the therapeutic developers and the patients who rely on their ground-breaking treatments.” Her passion for advancing innovative manufacturing processes for cell therapies underscores her commitment to the vision and mission of RoslinCT.
Expertise in the Field
With an extensive professional background, Dr. Carmen is well-equipped to take on her new responsibilities. Not only did she serve as Vice President of Business Development for Kincell Bio, but she also provided consultancy support to the business development team at Oxford Biomedica. Her broad technical knowledge of cell and gene therapies further enhances her ability to contribute meaningfully to RoslinCT's goals.
Background of RoslinCT
Founded in 2006, RoslinCT has established itself as a leading global contract development and manufacturing organization (CDMO) focusing on Advanced Cell and Gene Therapies. This innovative company originated from the pivotal cloning of Dolly the Sheep at the Roslin Institute, revolutionizing the field of biotechnology. Achievements include being one of the first entities to produce clinical-grade human pluripotent stem cells.
Innovations and Milestones
In partnership with various collaborators, RoslinCT successfully developed the first-ever CRISPR-edited cell therapy product, marking a substantial leap from early development to market readiness. Equipped with 22 state-of-the-art cGMP cell therapy processing suites in Edinburgh and Hopkinton, RoslinCT offers comprehensive services, including innovative process development, clinical and commercial manufacturing, and advanced analytical development.
Commitment to Advancing Therapeutics
RoslinCT is dedicated to empowering its partners with tailored CDMO solutions that facilitate the transition from development to commercialization of life-saving cell and gene therapies worldwide. As a proud member of the GHO Capital portfolio, the organization continues to position itself at the forefront of this rapidly evolving industry.
Frequently Asked Questions
Who is Jessica Carmen?
Jessica Carmen, Ph.D., is the newly appointed Chief Commercial Officer at RoslinCT, with over 20 years of experience in the cell and gene therapy industry.
What are Dr. Carmen's responsibilities at RoslinCT?
Dr. Carmen will lead and coordinate all commercial activities, including marketing, business development, and customer relations.
What is RoslinCT known for?
RoslinCT is recognized as a leading CDMO specializing in Advanced Cell and Gene Therapies, contributing significantly to the development of human medicines.
How many facilities does RoslinCT operate?
RoslinCT operates 22 cGMP cell therapy processing suites located in Edinburgh, Scotland, and Hopkinton, Massachusetts.
What notable product did RoslinCT develop?
RoslinCT developed the first CRISPR-edited cell therapy product for a major inherited disorder, showcasing their innovative capabilities.
